Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A C Ludolph

Showing results (21-30 of 172) with videos related to

Pageof 18
Sort By:
Journal of the Neurological Sciences|August 1, 1996
Toxic models of upper motor neuron diseaseA C Ludolph, P S Spencer
Journal of Neurology|August 29, 2009
Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). PrefaceA C Ludolph, V E Drory
Bailliere'S Clinical Neurology|November 1, 1995
Toxic neuropathies and their treatmentA C Ludolph, P S Spencer
Fortschritte Der Medizin. Originalien|February 24, 2001
[Normal and pathological aging of the brain]C A von Arnim, A C Ludolph
AJNR. American Journal of Neuroradiology|April 9, 2011
Alterations of the corpus callosum as an MR imaging-based hallmark of motor neuron diseasesA Unrath, A C Ludolph, J Kassubek
Journal of Neural Transmission (Vienna, Austria : 1996)|October 14, 2004
Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degenerationA Storch, A C Ludolph, J Schwarz
Journal of Inherited Metabolic Disease|January 1, 1993
Excitotoxicity, energy metabolism and neurodegenerationA C Ludolph, M Riepe, K Ullrich
Neurochemistry International|October 12, 1999
HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolismA Storch, A C Ludolph, J Schwarz
Lancet (London, England)|May 4, 1996
Skin involvement in amyotrophic lateral sclerosisG Kolde, R Bachus, A C Ludolph
European Journal of Pediatrics|July 1, 1996
Studies of multimodal evoked potentials in treated phenylketonuria: the pattern of vulnerabilityA C Ludolph, U Vetter, K Ullrich
Pageof 18

Showing results (21-30 of 172) with videos related to

Sort By:
Pageof 18
Journal of the Neurological Sciences|August 1, 1996
Toxic models of upper motor neuron diseaseA C Ludolph, P S Spencer
Journal of Neurology|August 29, 2009
Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). PrefaceA C Ludolph, V E Drory
Bailliere'S Clinical Neurology|November 1, 1995
Toxic neuropathies and their treatmentA C Ludolph, P S Spencer
Fortschritte Der Medizin. Originalien|February 24, 2001
[Normal and pathological aging of the brain]C A von Arnim, A C Ludolph
AJNR. American Journal of Neuroradiology|April 9, 2011
Alterations of the corpus callosum as an MR imaging-based hallmark of motor neuron diseasesA Unrath, A C Ludolph, J Kassubek
Journal of Neural Transmission (Vienna, Austria : 1996)|October 14, 2004
Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degenerationA Storch, A C Ludolph, J Schwarz
Journal of Inherited Metabolic Disease|January 1, 1993
Excitotoxicity, energy metabolism and neurodegenerationA C Ludolph, M Riepe, K Ullrich
Neurochemistry International|October 12, 1999
HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolismA Storch, A C Ludolph, J Schwarz
Lancet (London, England)|May 4, 1996
Skin involvement in amyotrophic lateral sclerosisG Kolde, R Bachus, A C Ludolph
European Journal of Pediatrics|July 1, 1996
Studies of multimodal evoked potentials in treated phenylketonuria: the pattern of vulnerabilityA C Ludolph, U Vetter, K Ullrich
Pageof 18